A New Era in Treating Depression – Sovereign Health Introduces Transcranial Magnetic Stimulation

Major Depressive Disorder is the leading cause of adult disability in America, accounting for $210 billion in economic burdens. The first line of treatment has traditionally been antidepressant medications. The likelihood of achieving remission with antidepressant medications is limited and declines with each successive treatment attempt. Deep Transcranial Magnetic Stimulation (dTMS) offers new hope for treatment resistant depression. FDA approved in 2008, dTMS clinical trials consistently indicate 50% remission outcomes, and as high as 75% response to treatment. Transcranial Magnetic Stimulation is a non-invasive, well-tolerated breakthrough in depression treatment.

Speaker : Manish Sheth, M.D., Ph.D

Post a comment

Subscribe to the Sovereign Health Group newsletter

Get the latest news on program developments, behavioral health news and company announcements.